These values were more than twice lower than ours: IgA aCL and IgA anti-β2-GP1 (42% and 41%) in patients with PAPS and these antibodies (59% and 47%) in those with secondary APS. The gene discussed is ACLY; the disease is autoimmune polyendocrinopathy.